Searching for a path forward after the withdrawal of Relyvrio in amyotrophic lateral sclerosis (ALS), Amylyx Pharmaceuticals has purchased a GLP-1 receptor antagonist from Eiger Biopharma for $35.1 million.
Amylyx to buy bankrupt Eiger`s experimental drug to treat low blood sugar
Amylyx Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
Biogen, Ionis to discontinue development of experimental ALS drug
Amylyx Pharmaceuticals Reports First Quarter 2024 Financial Results
Amylyx Pharmaceuticals to Present at the 2024 Bank of America Health Care Conference
The pharmaceutical and biotechnology industries are undergoing a significant upheaval, with a series of layoffs announced in April 2024 affecting numerous leading companies and hundreds of employees. These job cuts span a spectrum of reasons, from strategic realignment and cost-cutting measures to the fallout from unsuccessful drug trials and competitive market dynamics. This article explores the major layoffs that have unfolded, delving into the reasons behind them and their potential long-term impact on the industry.
Amylyx Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024
Amylyx stock slips 6% after phase 2 rare disease data drop
Amylyx Pharmaceuticals Announces Interim Data From Ongoing Phase 2 HELIOS Clinical Trial Demonstrating Improvements in Pancreatic Function and Glycemic Control with AMX0035 in People with Wolfram Syndrome